312 related articles for article (PubMed ID: 31699450)
61. Potential therapeutic targets beyond cytokines and Janus kinases for autoimmune arthritis.
Wu CY; Yang HY; Lai JH
Biochem Pharmacol; 2023 Jul; 213():115622. PubMed ID: 37230194
[TBL] [Abstract][Full Text] [Related]
62. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
63. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
64. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
65. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor.
Desai J; Patel B; Gite A; Panchal N; Gite S; Argade A; Kumar J; Sachchidanand S; Bandyopadhyay D; Ghoshdastidar K; Patel H; Chatterjee A; Mahapatra J; Sharma M; Giri P; Kumar S; Jain M; Sharma R; Desai R
Bioorg Med Chem Lett; 2022 Jun; 66():128728. PubMed ID: 35413417
[TBL] [Abstract][Full Text] [Related]
66. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease.
Siegmund B
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S761-S766. PubMed ID: 31922534
[TBL] [Abstract][Full Text] [Related]
67. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors.
Kato M
Immunol Med; 2020 Jun; 43(2):72-78. PubMed ID: 32338187
[TBL] [Abstract][Full Text] [Related]
68. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
69. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
70. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
71. Advanced nanomedicine approach of JAK inhibitors: supporting treatment of rheumatoid arthritis.
Rani R; Raina N; Kumar A; Gupta PK; Gupta M
Nanomedicine (Lond); 2024 Feb; 19(4):277-280. PubMed ID: 38214205
[No Abstract] [Full Text] [Related]
72. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
Yamaoka K
Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
[TBL] [Abstract][Full Text] [Related]
73. Immunosuppressive therapy in management of non-malignant disease.
Fennelly JJ; Fitzgerald MX; Fitzgerald O
J Ir Med Assoc; 1970 Apr; 63(394):141-6. PubMed ID: 5418154
[No Abstract] [Full Text] [Related]
74. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
75. [Janus kinase inhibitors : new perspectives for precision medicine ?].
Tachet J; Dumusc A; Conrad C; Grandoni F; Chalandon Y; Ribi C; Buclin T; Girardin F
Rev Med Suisse; 2022 Oct; 18(800):1979-1983. PubMed ID: 36259705
[TBL] [Abstract][Full Text] [Related]
76. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease.
Garrido I; Lopes S; Macedo G
Inflamm Bowel Dis; 2021 Nov; 27(12):2010-2022. PubMed ID: 33742651
[TBL] [Abstract][Full Text] [Related]
77. Small molecular compounds in development for rheumatoid arthritis.
van Vollenhoven RF
Curr Opin Rheumatol; 2013 May; 25(3):391-7. PubMed ID: 23492738
[TBL] [Abstract][Full Text] [Related]
78. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
79. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
80. JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus.
Moysidou GS; Dara A
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):37-44. PubMed ID: 38756931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
